NeuroHagana
Preventing Permanent Disabilities after Neurotrauma
Company Overview
Snapshot
Founded in March 2023 by Angela Ruban, NeuroHagana operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on developing an emergency treatment for neurotrauma. In May 2025, NeuroHagana was selected to join the SCI Incubate 2025 Cohort by the Praxis Spinal Cord Institute.
Business overview
NeuroHagana (NH) is a Health Tech & Life Sciences company developing an injectable emergency treatment for neurotrauma, designed to prevent permanent disabilities. Its core technology targets glutamate excitotoxicity, a primary factor in neurotrauma pathology, by reducing the toxic impact of excessive glutamate levels in the central nervous system. The company's product aims to prevent irreversible neuronal damage and physical disabilities, with initial applications focused on spinal cord injury in Europe and the USA, and future expansion to traumatic brain injury and stroke. NeuroHagana serves paramedics, hospital trauma units, first aid teams, and military forces, positioning its innovative drug as a vital component of emergency kits.
Strategic signal
In May 2025, NeuroHagana was selected for the SCI Incubate 2025 Cohort by the Praxis Spinal Cord Institute. This inclusion signals significant validation for NeuroHagana's innovative approach to neurotrauma treatment, providing access to specialized resources and expertise within the spinal cord injury community. For investors, this indicates strong potential for accelerated development and market entry, as well as a strategic alignment with a leading organization in the field.
Log in to access full profile ›Company Intelligence Q&A
- What is NeuroHagana's primary focus?
- NeuroHagana is focused on developing an injectable emergency treatment for neurotrauma, aiming to prevent permanent disabilities by addressing glutamate excitotoxicity.
- When was NeuroHagana founded?
- NeuroHagana was founded in March 2023.
- Who is the founder of NeuroHagana?
- Angela Ruban is the Co-founder & CEO of NeuroHagana.
- What significant program did NeuroHagana join in May 2025?
- In May 2025, NeuroHagana was selected to join the SCI Incubate 2025 Cohort by the Praxis Spinal Cord Institute.
- What markets does NeuroHagana target for its initial applications?
- NeuroHagana's initial applications for its emergency treatment for Spinal Cord Injury are targeted towards Europe and the USA.